Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ThyroSeq®V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 1 Sept 2018

Rivas Ana Marcella, Nassar Aziza, Zhang Jun, Casler John D, Chindris Ana Maria, Smallridge Robert, Bernet Victor

Abstract excerpt

OBJECTIVE: Approximately 15 to 30% of thyroid nodules have indeterminate cytology. Many of these nodules are treated surgically, but only 5 to 30% are malignant. Molecular testing can further narrow the risk of malignancy of these nodules. Our objective was to assess the cost effectiveness of ThyroSeq®V2.0 compared to diagnostic thyroidectomy for the evaluation of indeterminate nodules. METHODS: Cytology and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thyroid Nodule
Share to Thyroidectomy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy, Fine-Needle

Share to Cost-Benefit Analysis

Share to Health Care Costs

Share to Mutation

Source

Identifiers

PMID: 30084677
DOI: 10.4158/EP-2018-0212

Genes

SFN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ThyroSeq®V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules.PMID 30084677Read ↗

The utility of ThyroSeq® in the management of indeterminate thyroid nodules by fine-needle aspiration.Semantic proximity Read ↗

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.Semantic proximity Read ↗

Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.Semantic proximity Read ↗

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.Semantic proximity Read ↗

Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.Semantic proximity Read ↗

Current State of Molecular Cytology in Thyroid Nodules: Platforms and their Diagnostic and Theranostic UtilitySemantic proximity Read ↗

Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.Semantic proximity Read ↗

Molecular Testing of Thyroid Nodules: A Review of Current Available Tests for Fine-Needle Aspiration Specimens.Semantic proximity Read ↗

Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.Semantic proximity Read ↗

Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.Semantic proximity Read ↗

Clinicopathological, Molecular, and Economic Outcomes of Bethesda III and IV Thyroid Nodules Following Implementation of a Publicly Funded ThyroSeq v3 ProgramSemantic proximity Read ↗

Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.